OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy to be stopped in patients who are still responding. This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): Jan 20 2006

Volume: 24

Issue: 3

Affiliations

[1 ] Hôpital Saint-Antoine, Paris, France.

Article

Publisher Item ID: 24/3/394

DOI: 10.1200/JCO.2005.03.0106

PubMed ID: 16421419

SO-VID: 0a32aec0-d4f3-4ebe-a6c0-8815bd58c4d8

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.